1. Introduction
===============

Gastric cancer is the fourth most frequent cancer in the world, accounting for a large proportion of cancer cases in East Asia (China, Japan), Eastern Europe, and parts of Central and South America and it is the second most common cause of death from cancer [@B1]. *Helicobacter pylori* (*H. pylori*) strains carrying the cytotoxin-associated gene A (*cagA*) gene are strongly associated with increased risk of gastric adenocarcinoma [@B2]. However, only some of those infected developed*H. pylori*-related disease such as gastric ulcer, atrophy, cancer and so on. In Asian countries such as Japan with high prevalence of *cagA*-positive *H. pylori* infection, bacterial virulence factor has limitation of determining *H. pylori*-related disease. Therefore, we think it important to determine any host genetic predisposition to different outcome after the bacteria infection.

*H. pylori*, especially *cagA* positive strains, plays a crucial role in the development of gastric atrophy and cancer [@B2],[@B3]. CagA/ src homology 2 domain-containing protein tyrosine phosphatase-2 (SHP-2) interaction elicits cellular changes that increase the risk of carcinogenesis via extracellular-regulated protein kinase (ERK) activity [@B4],[@B5]. CagA is regarded as a bacterial protein that mimics mammalian docking/scaffolding molecule such as Grb2-associated binder 1 (Gab1) [@B6].

Gab1 consists of a pleckstrin homology domain, followed by a proline-rich region and multiple tyrosine phosphorylation sites that serve as binding sites for the SH2 domains of PI3-kinase, phospholipase Cγ, SHP2, and CrkL [@B7],[@B8]. Gab1 functions upstream of Ras/mitogen-activated proten kinase (MAPK) signaling pathway, most likely to regulate the activity of the GDP / GTP exchanger, in a variety of growth receptor signaling to activate ERK. SHP-2 is a ubiquitously expressed protein tyrosine phosphatase (PTPase) that contains two SH2 domains and an active catalytic domain [@B9],[@B10]. SHP-2 PTPase activity is required for activation of the ERK subfamily of MAPK by epidermal growth factor (EGF) [@B11],[@B12]. The previous reports suggest that the interaction between Gab1 and SHP2 is an essential component for ERK activation [@B13]-[@B17]. The activated SHP-2 is associated with Gab1 to mediate EGF-stimulated ERK2 activation, and Gab1 is the SHP-2 activator for the ERK MAP kinase pathway in EGF-stimulated cells [@B17].

We have reported previously that G/G of the *PTPN11* gene encoding SHP-2 increased the risk of gastric atrophy among the seropositive subjects [@B18]. The present study examined the association of a polymorphism of *Gab1* with gastric cancer and gastric atrophy identified as the precursor lesion of gastric cancer amongr the same Japanese subjects. There have been several SNPs identified in *Gab1*gene in the Japan Single Nucleotide Polymorphisms (JSNP) database (<http://snp.ims.u-tokyo.ac.jp>). A particularly prevalent SNP is reported in intron 2 (G/A)*,*identified as JST164345 in JSNP database. The gene-gene interaction between *PTPN11*and*Gab1* was also evaluated.

2. Materials and methods
========================

Patients
--------

The clinical characteristics of the subjects were described in our previous paper [@B18]. Briefly, the control group was 454 health checkup examinees (HCE) without a history of cancer (126 males and 328 females) aged 35 to 85, who attended a health checkup program supported by the Nagoya municipal government, in August and September 2000. The study protocol was approved by the Ethics Committee of the Aichi Cancer Center, with which the chief investigation (N.H.) was affiliated at the enrollment of study subjects. The case group was 202 patients (134 males and 68 females) aged 33 to 94 with pathologically confirmed diagnosis of gastric adenocarcinoma, who underwent tumor resection in different affiliated hospitals of Nagoya University between January 1998 and June 2000. Informed consent was obtained from all the subjects. This study protocol was approved by the Ethics Committee of the Nagoya University Graduate School of Medicine.

Tests for Helicobacer pylori (H. pylori) antibody and pepsinogens
-----------------------------------------------------------------

Anti-*H. pylori* IgG antibody tests, high-molecular- weight campylobacter-associated-protein (HM-CAP) ELISA (Enteric Products Inc., Westbury, NY) and HM-CAP with antigens extracted from clinically isolated Japanese *H. pylori* strains (J-HM-CAP) ELISA (Kyowa Medex, Tokyo, Japan), were used for the identification of *H. pylori*-infected participants (in the control group the former was used and in the case group both were used.). An ELISA value of 2.3 or over was regarded as positive for both tests. The infection was confirmed in all gastric cancer cases by culture and bacteriological tests (Gram-negative, oxidase, catalase, and urease test--positive spiral, curved rods) using biopsy specimens before gastric resection. Pepsinogens I and II (PG I and PG II) in serum were measured by radioimmunoassay using a commercially available kit (DINABOT, Tokyo, Japan). Gastric atrophy was defined as PG I\< 70 ng/ml and PG I/PG II ratio \<3.

Genotype Assessment
-------------------

DNA was extracted from buffy coat fraction by Qiagen QIAamp DNA Blood Mini Kit (QIAGEN Inc.,Valencia,CA). A single nucleotide polymorphism (SNP) at intron 2 of *Gab1,*named as JST164345 in a database of Japan Single Nucleotide Polymorphisms (JSNP) at <http://snp.ims.u-tokyo.ac.jp>, was genotyped by PCR-CTPP (polymerase chain reaction with confronting two-pair primers) [@B19]. The primers were F1: 5\' GGT TTA AAC TTT ATT CTG ACT GTT CCC, R1: 5\' ACA CAA TTT AGT AAT AGC CAA AGT CAA C, F2: 5\' GTT GTT GTG AAG TAG AAA CTG ATT TCT AA, and R2: 5\' CTG GGG AGT GGG CCA. Genomic DNA was applied in a volume of 25 ul with 0.12 mM dNTPs, 25 pmol of each primer, 0.5 units of AmpliTaq Gold (Perkin-Elmer Corp., Foster City, CA), and 2.5 ul 10xPCR buffer including 15mM MgCl2. The PCR was performed with initial denaturation at 95 ℃ for 10 minutes, followed by 30cycles of denaturation at 95 ℃ for 1 minute, annealing at 63.5 ℃ for 1 minute and extension at 72℃ for 5 minutes. The final extension was at 72 ℃ for 5 minutes. Figure [1](#F1){ref-type="fig"} shows the results of PCR-CTPP for*Gab1*. PCR product was visualized on a 2% agarose gel with ethidium bromide staining. A SNP of *PTPN11* that encodes SHP-2 (JST057927) was genotyped as reported in our previous report [@B19].

Statistical analysis
--------------------

To prevent confounding bias, odds ratios (ORs) adjusted for sex and age with 95% confidence intervals (CIs) were calculated using logistic regression analysis.

The Hardy- Weinberg equilibrium was examined for discrepancy between genotype and allele distributions using a χ² test.

The product variable between gene and gene was included in the logistic model to evaluate the multiplicative interactive effect of genes. All tests were 2-tailed with statistical significance setting at the level of p\<0.05. Hardy-Weinberg equilibrium was tested for the*Gab1* polymorphism. These calculations were performed by computer program STATA Version 8 (STATA Corp, College Station, TX).

3. Results
==========

Study characteristics
---------------------

Although these summary has been described previously [@B18], it is shown here again for the readers\' convenience (Table [1](#T1){ref-type="table"}). The prevalence of *H. pylori* seropositivity was significantly higher in the gastric cancer cases than in the healthy controls (100% vs. 55.1%, p\<0.001). One hundred seventy-nine of the 202 (89%) gastric cancer cases had atrophy with significantly higher prevalence than the control group (35%). Atrophy was present in 54.8% of the 250 *H. pylori* seropositive healthy controls, which was significantly lower than the seropositive gastric cancer cases (p=0.001) but significantly higher than the seronegative healthy controls in which atrophy was present in only 10% of subjects (p\<0.001).

Gab1 polymophism and H. pylori infection risk
---------------------------------------------

The *Gab1* genotype distribution of the control group was in the Hardy-Weinberg equilibrium (χ²=2.50, P=0.11). Table [2](#T2){ref-type="table"} shows that the genotype frequency and odds ratio (OR) of *H. pylori*seropositivity in healthy controls. The seropositivity rate for those with A/A was lowest. The decreased OR of A/A for *H. pylori*seropositivity was 0.25 (95% CI: 0.08-0.71). Twenty-one of the 204 seronegative healthy controls (10%) had atrophy, which were considered as the loss of*H. pylori* infection following sever atrophy. To ascertain whether the reduced infection risk related to this polymorphism follows sever atrophy, we arranged category so as to classify 21 seronegative controls with atrophy as seropositive controls. We calculated the OR for *H. pylori*again and the corresponding OR was also a decreased risk with significance (OR=0.25, 95% CI: 0.09-0.71).

The combination of Gab1 and PTPN11and H. pylori-related gastric atrophy
-----------------------------------------------------------------------

We have got subjects narrowed down to *H. pylori* seropositive healthy controls because of our interest in the association between these polymorphisms and digestive disease caused by*H. pylori* infection. We have reported previously that *G/G*of the *PTPN11* gene encoding SHP-2 increased the risk of gastric atrophy [@B18]. Table [3](#T3){ref-type="table"} shows the age-sex-adjusted ORs of the *Gab1* and the combinations of *PTPN11*and*Gab1* genotypes for gastric atrophy among seropositive healthy controls. The OR of G/A+A/A for gastric atrophy was significant (OR=1.95, 95% CI 1.12 -3.40). Seropositive individuals with the *PTPN11*G/G and *Gab1*G/A+A/A demonstrated the highest risk of gastric atrophy with significance relative to *PTPN11*G/A+A/A and *Gab1*G/G, the lowest risk combination, as a reference. However, the gene-gene interaction between the *PTPN11*and the*Gab1*was not observed (OR=1.39, 95% CI 0.41-4.66).

Gab1 polymorphism and the step of atrophy/metaplasia-gastric cancer
-------------------------------------------------------------------

We assessed whether the *Gab1* gene polymorphism was associated with the development of *H. pylori*-related gastric cancer. Table [4](#T4){ref-type="table"} shows the genotype frequency and ORs of the *Gab1* genotypes for gastric cancer among the seropositive subjects. The *Gab1*gene was not associated with the risk of gastric cancer among the seropositive subjects. In order to find out if the *Gab1* polymorphism influenced the step of atrophy/metaplasia-gastric cancer sequence, proposed as the Correa cascade [@B20], we made a comparison between cases and controls with seropositive atrophy. The ORs of the G/A and A/A for gastric cancer was 1.05 (95% CI 0.63-1.74) and 1.05 (95% CI 0.27-4.07), respectively.

4. Discussion
=============

This epidemiologic finding that the *Gab1* polymorphism was associated with *H. pylori*seropositivity and gastric atrophy is plausible. However, the *Gab1* polymorphism did not influence the development of gastric cancer.

The Gab1 A/A decreased the risk of *H. pylori* seropositivity, whereas the Gab1 G/A+A/A was associated with gastric atrophy risk. In order to find out if the *Gab1* polymorphism relates to loss of *H. pylori* infection following severe atrophy, which has been reported [@B21], we classified 21 seronegative controls with atrophy, which might be eradicated naturally, as seropositive controls. If the decreased OR for *H. pylori*seropositivity under this condition is not significant, we could conclude that the *Gab1*polymorphism is associated with severe atrophy which induces the chance of natural eradication of the bacteria. However, the OR of the A/A genotype for*H. pylori* seropositivity was 0.25 (95% CI 0.09-0.71). So, the *Gab1* polymorphism was associated with the low risk of the infection independent on severe atrophy. Although the *Gab1* polymorphism prevented*H. pylori* infection, it was associated with the risk of atrophy identified as the precursor lesion of gastric cancer but not severe atrophy which is a final stage of atrophic status and loses*H. pylori* infection. Gab1 plays important roles in the signal transduction of cytokines, growth factors, antigen receptors [@B22]. The association between the polymorphism of cytokine genes such as*interleukin 1B*[@B23],[@B24] and *tumor necrosis factor A*[@B25],[@B26] and *H. pylori* seropositivity have been reported. Gab1 may affect the *H. pylori* infection through the level of cytokines which are advantageous to eradication of *H. pylori*.

These results should be interpreted with caution. The question is whether these apparently *H. pylori*-negative subjects were indeed truly negative or they eventually led to loss of the infection due to sever gastric atrophy. Because, in our study, gastric atrophy and*H. pylori*infection were based on serological diagnosis and the diagnosis happened to be imperfect, we might not discriminate severe atrophy exactly and further biological studies with histological assessment are needed to confirm the association. The functional changes caused by *Gab1* polymorphism are not known and may be linkage disequilibrium with another gene. These are deficiencies of this study but we hope that our epidemiological and biologically plausible observation would stimulate interest in the study of the molecular mechanisms of action of this polymorphism. Because these results were based on the low frequency of *A/A*, they might be inconsistent due to the random errors. Studies of a larger size are needed to confirm our finding. This study, however, had 80% power to detect an absolute difference in the frequency of G/A+A/A, given 44% in the case and 56% in the control.

The *PTPN11*polymorphism was associated with gastric atrophy among seropositive subjects [@B18]. The two tyrosine residues (Tyr-627 and Tyr-659) in the carboxyl-terminal region of Gab1 are required for SHP-2 binding to Gab1 and for EGF-stimulated ERK activation, in which another study reported Gab1/SHP-2 interaction was independent of ERK activation [@B27]. Tyr-627 and Tyr-659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) that binds to and activates SHP-2 [@B17]. Two SH2 domaines of SHP-2, termed N-SH2 and C-SH2 domaines, are arranged in tandem at the amino (N)-terminal portion. SHP-2 has a low basal PTPase activity that can be activated by deletion of N-SH2 or both SH2 domains or by specific phosphopeptides that bind to the SH2 domains. The tandem SH2 domains bind to Tyr-627 and Tyr-659 simultaneously in a specific orientation, in which Tyr-627 binds to the N-SH2 domain and Tyr-659 binds to the C-SH2 domain [@B17]. Experiments with Gab1 mutants which are unable to bind to SHP-2 indicate that the interaction between SHP-2 and Gab1 and the activation of SHP-2 are essential for ERK activation [@B28]-[@B30]. The*Gab1*polymorphism may affect the interaction with SHP-2 through the mechanism such as BTAM after*H pylori* infection, resulting in influencing the abnormal proliferation and movement of gastric epithelial cells related to gastric atrophy via the activation of ERK.

This study also showed that the gastric atrophy risk was highest for those who carry the PTPN11 G/G and Gab1 G/A+A/A among seropositive subjects without interaction between those genotypes. Considering the mechanism such as BTAM, the epidemiologic interaction was expected, but not observed.

Among the seropositive subjects, the *Gab1*polymorphism was not associated with gastric cancer. When we made a comparison between cases and controls with seropositive atrophy, the ORs of G/A and A/A for gastric cancer were also each insignificant. This result showed that this polymorphism did not influence the step of atrophy/metaplasia-gastric cancer sequence. As discussed in our previous report [@B18], our all gastric cancer cases had evidence of*H. pylori* infection because of the earlier presentation or diagnosis of cancer.

In summary, the Gab1 A/A was associated with the low risk of *H. pylori*infection while the G/A and A/A genotypes together may increase the risk for gastric atrophy. The biological mechanism of this polymorphism remains to be elucidated. In addition, individuals with the PTPN11 G/G and Gab1 G/A+A/A demonstrated the greatest risk of gastric atrophy with no interaction. Our data provided further evidence for host genetic factors in the susceptibility to *H pylori* infection and *H. pylori*-related gastric atrophy. Further investigation of the association requires much larger studies, as well as confirmatory biological studies with histological assessment.
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###### 

Characteristics of the study subjects by source of recruitment.

                                           Cases n(%)   Controls n(%)
  ---------------------------------------- ------------ ---------------
  Number of subjects                       202          454
  Age in years (mean±standard deviation)   66.7±12.3    58.4±11.9
  Sex                                                   
  Male                                     134 (66.3)   126 (27.8)
  Female                                   68 (33.7)    328 (72.3)
  *H. pylori* antibody                                  
  Negative                                 0 (0)        204 (44.9)
  Positive                                 202 (100)    250 (55.1)
  Gastric atrophy                                       
  Negative                                 23 (11.4)    296 (65.2)
  Positive                                 179 (88.6)   158 (34.8)

###### 

Genotype frequency and odds ratios (ORs) and 95% confidence intervals (95%CIs) of *H. pylori*Seropositivity (*HP+*) in Healthy Checkup Examinees.

  Genotype   n     *HP+* (%)    OR^a^(95%CI)
  ---------- ----- ------------ ------------------
  G/G        317   171 (53.9)   1.00 (Reference)
  G/A        119   74 (62.2)    1.30 (0.81-2.07)
  A/A        18    5 (27.8)     0.25 (0.08-0.71)
  G/A+A/A    137   79 (57.7)    1.02 (0.67-1.56)

^a^Sex-age-adjusted odds ratio

###### 

ORs and 95% CIs for gastric atrophy (GA) of *Gab1* and the combinations of *PTPN11*and *Gab1*genotypes among seropositive healthy controls.

  Genotype    n         GA (%)       OR^a^(95%CI)       
  ----------- --------- ------------ ------------------ ------------------
  Gab1                                                  
  G/G         171       85 (49.7)    1.00 (Reference)   
  G/A         74        48 (64.9)    1.87 (1.06-3.29)   
  A/A         5         4 (80.0)     4.24 (0.45-39.7)   
  G/A+A/A     79        52 (65.8)    1.95 (1.12-3.40)   
  Total       250       137 (54.8)                      
  PTPN11^b^   Gab1                                      
  G/A+A/A     G/G       49           20 (40.8)          1.00 (Reference)
  G/A+A/A     G/A+A/A   23           12 (52.2)          1.57 (0.58-4.29)
  G/G         G/G       121          64 (52.9)          1.60 (0.82-3.15)
  G/G         G/A+A/A   55           39 (70.9)          3.49 (1.54-7.90)
  Total       248       135 (54.4)                      

^a^Sex-age-adjusted odds ratio

^b^Two subjects could not be genotyped for PTPN11

###### 

The *Gab1*genotype frequency and ORs for gastric cancer among the seropositive subjects.

  Genotype   Cases n   Controls n   OR^a^ (95%CI)
  ---------- --------- ------------ -------------------
  G/G        119       171          1.00 (Reference)
  G/A        75        74           1.35 (0.88- 2.07)
  A/A        8         5            1.53 (0.46- 5.10)
  G/A+A/A    83        79           1.36 (0.90-2.06)
  Total      202       250          

^a^Sex-age-adjusted odds ratio
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